Roche reports very strong growth in the first nine months of 2018

Added: 1 month ago by Roche

Visit the Roche Company Hub


Roche reports very strong growth in the first nine months of 2018

  • Group sales increase 7% at constant exchange rates and in Swiss francs
  • Pharmaceuticals Division sales up 7%, driven mainly by Ocrevus, Perjeta, Alecensa and Tecentriq
  • Diagnostics Division sales grow 6%, primarily due to demand for immunodiagnostic solutions
  • Recent approvals: Hemlibra for people with haemophilia A without factor VIII inhibitors, Actemra sub-cutaneous formulation for active systemic juvenile idiopathic arthritis and prefilled syringes for Xolair in the US; Alecensa for a form of lung cancer in China
  • Outlook for 2018 confirmed.
Visit the Roche Company Hub

Tagged as: Industry News